Strategies to inhibit the JAKs/STAT3 pathway prove instrumental in mitigating immune tolerance in cancer cells, with tangible outcomes observed in restraining tumor invasion and growth in xenografts (52, 54, 62). This evidence concerns the gene STAT3 and cancer.